OptiNose (OPTN) Prices 25M Share Offering at $1.60/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Optinose (OPTN) PT Lowered to $9 at BMO Capital
November 17, 2021 9:08 AM ESTBMO Capital analyst Gary Nachman lowered the price target on Optinose (NASDAQ: OPTN) to $9.00 (from $16.00) while maintaining an Outperform rating.
The analyst commented, "3Q Xhance revenue was slightly below and 2021 guidance lowered given continued COVID-19 headwinds impacting sales access and Rx volumes (though... More
After-Hours Stock Movers 11/15: (AXON) (RMO) (RPRX) Higher; (BODY) (OPTN) (CLOV) Lower (more...)
November 15, 2021 6:02 PM ESTAfter-Hours Stock Movers:
Beachbody Company (NYSE: BODY) 21% LOWER; reported Q3 EPS of ($0.13), $0.02 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $208.1 million versus the consensus estimate of $246.93 million. Beachbody Company sees FY2021 revenue of $820-830 million, versus the consensus of $964 million.
Axon Enterprise, Inc. (NASDAQ: AXON) 19% HIGHER; reported revenue growth of 39% to $232 million, and GAAP net income of $49 million, which supported Adjusted EBITDA of $51 million, representing a 22% margin. Net income was favorably... More
OptiNose (OPTN) Announces Proposed Public Offering of Common Stock
November 15, 2021 5:41 PM ESTOptinose (NASDAQ: OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All shares of... More
